Electroporation platform for rapid tumor-reactive T cell
This technology uses precisely controlled electrical pulses to kill tumor cells in a way that makes their contents visible to the immune system. Those electrically treated tumor cells are then mixed with immune cells — specifically the T cells that kill cancer — causing those T cells to learn to recognize and attack that tumor. The activated T cells are then expanded in large numbers and can be infused back into a patient as a personalized cancer therapy. Essentially, this is a manufacturing process for growing a patient's own tumor-fighting T cells using electroporation instead of conventional chemical or genetic stimulation methods.
What you could build
A cell therapy manufacturing platform — either a device plus protocol kit or a contract manufacturing service — that produces personalized tumor-infiltrating lymphocyte (TIL) or CTL therapies for cancer patients; buyers would be cell therapy CDMOs, academic medical centers running adoptive cell therapy trials, and ultimately cancer therapy companies seeking a faster or cheaper TIL expansion workflow.
Who in Virginia should care
Virginia-based NCI-affiliated research hospitals, Inova's cancer programs, or cell therapy CDMOs operating in the broader Mid-Atlantic corridor would be natural early partners or licensees.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Rafael V. Davalos, Irving C. Allen, Scott S. Verbridge, Nastaran Alinezhadbalalami
- Filed
- Patent pending — filed March 22, 2023
- Status
- Application
- Publication number
- US20230355968A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.